Goldman Sachs has revealed a number of stocks that it says are highly attractive. Wall Street investment banks said there is plenty of upside for companies including Nvidia amid market volatility. Other buy-rated stocks reviewed by CNBC Pro include Teva, Philip Morris, S&P Global, and Apollo. Goldman Sachs says Teva Teva’s stock has doubled in the past year, but concerns that it’s going too far, too fast are overblown. Analyst Matt Delatorre and his team said pharmaceutical stocks are very attractive at current levels and investors should remain calm. “While this concern is understandable from a risk-reward perspective, I would like to emphasize that the company’s outlook today is fundamentally different than it was a few years ago, and therefore comparisons to historical multiples are becoming increasingly irrelevant,” he said. Analysts said shareholders should continue accumulating shares as Teva has a strong pipeline and earnings are on a rapid upward trajectory. Delatorre also raised his price target to $45 per share from $36. The company’s stock price has increased more than 8% since the beginning of the year. Philip Morris Tobacco giant is also firing up cylinders. Analyst Bonnie Herzog and her team said in a recent note that the stock has plenty of upside potential. “PM is transforming into a faster-growing and more profitable business – a profit-growing company with attractive valuations,” she wrote. Goldman also said it likes management’s aggressive outlook for 2026. He continued, “Simply put, there aren’t many Staples companies today that are delivering (and guiding) high-single-digit top lines with volume and impressive (double-digit) dollar-dollar EPS growth.” The stock is up about 18% this year. Analyst George Tong said capital markets firm S&P Global Shares has plenty of room to rise further, especially after falling 7% this week. “Strong AI positioning, conservative upside guidance, and sustained long-term profitability,” he wrote following the company’s recent quarterly earnings report. Tong lowered his price target to $498 per share from $555, but said he believes S&P Global has the talent to withstand any disruption caused by artificial intelligence. These concerns have weighed on S&P Global stocks recently. He continued, “Over the long term, we believe SPGI will drive sustained mid-to-high single-digit organic revenue growth and continued EBITDA margin expansion by expanding into high-growth adjacent regions, including private markets and decentralized finance, and strengthening our corporate capabilities.” The stock is down 22% this year. Nvidia: “We expect investors to focus on (1) directional commentary on the outlook for 2027, (2) non-traditional customer demand trends, (3) competitive dynamics, and (3) business trends in China. Given the favorable industry supply and demand data points, we expect a beat-and-raise quarter, but we believe the bar for outperformance is high heading into the quarter.” S&P Global “Powerful AI positioning, upward conservative guidance, and durable long-term profitability. …Longer term, SPGI’s expansion into high-growth adjacent regions, including private markets and decentralized finance, and the strengthening of its corporate capabilities will result in sustained mid-to-high single-digit organic revenue growth and continued EBITDA. Teva: “While we acknowledge this concern from a risk-reward perspective, we would like to emphasize that the company’s outlook today is fundamentally different than it was a few years ago, and therefore comparisons to historical multiples are increasingly irrelevant.” Philip Morris: “PM is growing faster and growing faster. “Simply put, there aren’t many Staples companies today that are achieving (and leading) high-single-digit top lines with volume and impressive DD/$$ EPS growth.” “We believe APO is relatively insulated from the industry-level risks that have weighed on Alts shares in recent months, and we see it as one of the few alternative asset managers with healthy upside potential to its 2026/27 numbers. With the stock currently trading at less than 14 times SBC-bearing 2027 DE on our latest estimates, we believe the stock is attractively priced out to 2026.”
